Ameriprise’s Bicycle Therapeutics BCYC Stock Holding History

Ameriprise’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,972	Closed	-$116K	–	4087
2025 Q3	$116K	Buy	14,972 +2,668	+22%	+$20.1K	﹤0.01%	3967
2025 Q2	$85.5K	Buy	+12,304	New	+$98K	﹤0.01%	3892

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

GSK plc London $599M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise's BCYC Position: Q4 2025 in Review

Ameriprise sold out of Bicycle Therapeutics (BCYC) in Q4 2025, closing a stake of 14,972 shares — an estimated $116K sold.

Ameriprise first reported a position in BCYC in Q2 2025 and held it in 2 quarters. The position peaked at $116K in Q3 2025. 109 funds tracked by Wall St. Rank hold BCYC as of Q4 2025.

Ameriprise reported no remaining Bicycle Therapeutics position as of Q4 2025 after selling out during the quarter.
Ameriprise sold 14,972 Bicycle Therapeutics shares in Q4 2025, an estimated $116K.
Ameriprise first reported a position in Bicycle Therapeutics in Q2 2025 and held it in 2 quarters.
Ameriprise's Bicycle Therapeutics position peaked at $116K in Q3 2025.
109 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.